Volume-Based Purchasing Looms Larger In Post-Coronavirus China

Big Price Cuts In New Round

China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.

Clouds-Lightning-Storm_1200x675
EXPANDED VOLUME-BASED PURCHASING LOOMS LARGER FOR PHARMA IN CHINA • Source: Shutterstock

China is expanding a volume-based purchasing scheme for drugs and the second round of the “4+7” centralized drug procurement program for major cities, announced right before the lunar new year in late January, has had a ripple effect on pharma companies across the country.

Out of a total of 33 drugs selected by the National Medical Insurance Administration, 32 have secured winning bids, showing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip